Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cymbalta fibromyalgia indication

Executive Summary

Lilly may be able to offer an alternative fibromyalgia treatment to Pfizer's Lyrica (pregabalin) by June 2008 if its sNDA for Cymbalta (duloxetine) is approved within a standard 10-month review. The filing was announced by the company Aug. 21. Cymbalta is approved for treatment of major depressive disorder, management of diabetic peripheral neuropathic pain and treatment of generalized anxiety disorder in adults. Separately, Lilly released clinical trial data for the serotonin-norepinephrine reuptake inhibitor showing greater reductions in pain severity one week after starting treatment compared to placebo. The sNDA is based on data from 1,400 patients across five clinical trials, the firm said. Pfizer has estimated the fibromyalgia indication could add $1 billion in incremental sales for Lyrica (1"The Pink Sheet" July 2, 2007, p. 17)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel